Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study
SGLT2i use in CKD patients during Ramadan fasting does not increase the risk of AKI. These findings may offer valuable guidance for clinicians managing fasting patients with CKD on SGLT2i therapy.
Authors
- Rowan Zyada (ORCID: https://orcid.org/0000-0002-1455-9046)
- Merna Mahmoud AbouKhatwa (ORCID: https://orcid.org/0000-0003-2610-7183)
- Ahmed Elkeraie (ORCID: https://orcid.org/0000-0002-0305-2290)
- Mohammed Elraggal
- Mariam E. Omar
Institutions
- Saudi Aramco Medical Services Organization (SA)
- Colorado Kidney Care (US)
- Alexandria University (EG)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s40620-025-02438-8
- Primary Topic
- Dietary Effects on Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00